WALTHAM, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences. The four conferences are:
- The Wells Fargo Global Healthcare Conference at the Westin Boston Waterfront in Boston on Wednesday, September 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will participate in an analyst-led moderated Q&A from 3:30 to 4:00 PM ET and in meetings with investors.
- The 11th Annual Citi Biotech Day at the Mandarin Oriental Hotel in Boston on Thursday, September 8, 2016. Lonnie Moulder will participate in a panel titled “Developing Cancer Therapeutics in 2016” at 8:00 AM ET. Also, Lonnie Moulder and Mary Lynne Hedley, Ph.D. will host meetings with investors.
- The Baird 2016 Healthcare Conference at the New York Palace Hotel in New York City on Thursday, September 8. Tim Pearson, EVP and CFO of TESARO, is scheduled to participate in an analyst-led fireside chat from 12:15 to 12:45 PM ET, and in meetings with investors.
- The Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology at the Lotte New York Palace in New York City on September 29, 2016. Lonnie Moulder and Jeff Hanke, Ph.D., EVP and Chief Scientific Officer of TESARO, will participate in an analyst-led fireside chat from 1:00 to 1:30 PM ET, and in meetings with investors.
Live webcasts of the presentations at the Wells, Baird and Leerink conferences and the panel at the Citi conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
For additional information, please contact: Jennifer Davis 1.781.325.1116 firstname.lastname@example.org